PMID- 25190663
OWN - NLM
STAT- MEDLINE
DCOM- 20141222
LR  - 20220309
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Linking)
VI  - 55
IP  - 10
DP  - 2014 Sep 4
TI  - A quantitative approach to identify morphological features relevant for visual 
      function in ranibizumab therapy of neovascular AMD.
PG  - 6623-30
LID - 10.1167/iovs.14-14293 [doi]
AB  - PURPOSE: To quantitatively analyze morphological features in eyes with 
      neovascular AMD (nAMD) at baseline, after 12 months, and after 24 months of 
      intravitreal ranibizumab treatment and to perform a structure/function 
      correlation. METHODS: Eyes with treatment-naive nAMD were treated with 
      intravitreal ranibizumab according to a standardized dosing regimen over 2 years 
      and followed continuously in a prospective study design. The central foveal area 
      of 1000 mum (horizontal)x960 mum (vertical) of spectral-domain optical coherence 
      tomography (SD-OCT) volume scans was evaluated quantitatively (using proprietary 
      software) for the following pathologies: alteration of the external limiting 
      membrane (ELM), alteration of the ellipsoid zone, subretinal fluid, pigment 
      epithelium detachment, drusen, intraretinal cysts, subretinal mass, and 
      subretinal pigment epithelium mass. The total area of each pathology was 
      calculated in mm2 at baseline and after 1 and 2 years of ranibizumab therapy and 
      correlated with BCVA results. RESULTS: In total, 480 central SD-OCT scans of 20 
      consecutive patients were evaluated. In the multivariate regression analysis, the 
      area of ELM alteration, the area of intraretinal cysts, and foveal retinal 
      thickness were significant variables influencing visual acuity at baseline 
      (R=-0.827; R2=0.684; P<0.001). The area of ELM alteration was the only 
      significant factor to be directly associated with visual acuity at 12 months 
      (R=-0.846; R2=0.716; P<0.001) and 24 months (R=-0.778; R2=0.606; P<0.001). 
      CONCLUSIONS: The integrity of the ELM appears to be the most important feature 
      correlating with visual acuity in native nAMD as well as nAMD treated with 
      intravitreal ranibizumab at each time interval, but not prospectively. In 
      general, no significant predictors for an individual gain or loss in mid- (12 
      months) or long-term BCVA results (24 months) were found by OCT.
CI  - Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
FAU - Roberts, Philipp
AU  - Roberts P
AD  - Department of Ophthalmology and Optometry of the Medical University Vienna, 
      Vienna, Austria.
FAU - Mittermueller, Tamara Jasmin
AU  - Mittermueller TJ
AD  - Department of Ophthalmology and Optometry of the Medical University Vienna, 
      Vienna, Austria.
FAU - Montuoro, Alessio
AU  - Montuoro A
AD  - Department of Ophthalmology and Optometry of the Medical University Vienna, 
      Vienna, Austria.
FAU - Sulzbacher, Florian
AU  - Sulzbacher F
AD  - Department of Ophthalmology and Optometry of the Medical University Vienna, 
      Vienna, Austria.
FAU - Munk, Marion
AU  - Munk M
AD  - Department of Ophthalmology and Optometry of the Medical University Vienna, 
      Vienna, Austria.
FAU - Sacu, Stefan
AU  - Sacu S
AD  - Department of Ophthalmology and Optometry of the Medical University Vienna, 
      Vienna, Austria.
FAU - Schmidt-Erfurth, Ursula
AU  - Schmidt-Erfurth U
AD  - Department of Ophthalmology and Optometry of the Medical University Vienna, 
      Vienna, Austria.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20140904
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fluorescein Angiography
MH  - Follow-Up Studies
MH  - Fundus Oculi
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Degeneration/drug therapy/*pathology/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Ranibizumab
MH  - Retinal Neovascularization/drug therapy/*pathology/physiopathology
MH  - Retinal Pigment Epithelium/drug effects/*pathology
MH  - Tomography, Optical Coherence
MH  - Treatment Outcome
MH  - *Visual Acuity
OTO - NOTNLM
OT  - neovascular AMD
OT  - ranibizumab
OT  - spectral-domain OCT
EDAT- 2014/09/06 06:00
MHDA- 2014/12/23 06:00
CRDT- 2014/09/06 06:00
PHST- 2014/09/06 06:00 [entrez]
PHST- 2014/09/06 06:00 [pubmed]
PHST- 2014/12/23 06:00 [medline]
AID - iovs.14-14293 [pii]
AID - 10.1167/iovs.14-14293 [doi]
PST - epublish
SO  - Invest Ophthalmol Vis Sci. 2014 Sep 4;55(10):6623-30. doi: 10.1167/iovs.14-14293.